89 results
Page 2 of 5
424B5
tg8dz9ermzxh5f29cqp7
24 Mar 22
Prospectus supplement for primary offering
4:15pm
424B5
1xv3svmyvi46 fc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.1
tro mavz0
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-10.1
zmqprj j5sgzp0clfe6
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-99.1
umf3vwt
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
424B3
39nvc4mi51owbr
12 Apr 21
Prospectus supplement
1:44pm
S-3
seyigwgfixy 3v
2 Apr 21
Shelf registration
12:00am
8-K
s406qx4g
5 Nov 20
Processa Pharmaceuticals Announces the Appointment of
9:00am
8-K
EX-99.1
989fu r49
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
424B4
42m n0rvi
5 Oct 20
Prospectus supplement with pricing info
4:16pm